Search | Clinical Trials Finder

Conditions: HIV Infections
Interventions: VRC-HIVDNA009-00-VP; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 5
States / cities: San Diego, California • Boston, Massachusetts • New York, New York + 1 more

Conditions: Stroke, Ischemic Stroke
Interventions: Intravenous Thrombolysis, Endovascular Arterial Reperfusion; Drug · Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: HIV-1-infection
Interventions: VRC07-523LS, PGT121.414.LS; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 10
States / cities: Birmingham, Alabama • San Diego, California • Aurora, Colorado + 7 more

Conditions: HIV Infections
Interventions: Patients elected to take licensed drugs. The vaccine was not provided for evaluation, multiple licensed drugs not randomized, multiple licensed antiretroviral drugs; not randomized, Intended vaccine not provided, Licensed drugs provided, but were not investigated; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: Ritonavir, Abacavir sulfate, Amprenavir, Lamivudine, Stavudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 18
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 10 more

Conditions: HIV Infections
Interventions: Dendritic Cells Pulsed with HIV antigens; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2000
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Fracture; Pelvic, Insufficiency Fractures, Fragility Fracture, Sacroiliac; Fusion, Sacroiliac Joint Disruption, Sacroiliac Joint Dysfunction
Interventions: iFuse TORQ TNT Implant System; Device
Lead sponsor: SI-BONE, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Rochester, Minnesota • Wyomissing, Pennsylvania

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: Decitabine, Venetoclax, FHD-286; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Peripheral Nerve Injury
Interventions: Polyethylene glycol (PEG); Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Acute Myeloid Leukemia
Interventions: Usual Care, Psychological intervention; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Acute Viral Respiratory Infection
Interventions: PurInf I Botanical Formulation, PurInf II Botanical Formulation, PurInf III Botanical Formulation, PurCo Botanical Formulation, PurPhl Botanical Formulation, PurClo Botanical Formulation; Drug
Lead sponsor: All Natural Medicine Clinic, LLC; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: HIV Infections
Interventions: Tenofovir disoproxil fumarate/Emtricitabine, Lopinavir/Ritonavir; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Denver, Colorado • Atlanta, Georgia

Conditions: HIV Infections
Interventions: MRKAd5 HIV-1 gag/pol/nef, MRKAd5 HIV-1 gag/pol/nef placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 13
States / cities: San Diego, California • San Francisco, California • Torrance, California + 7 more

Conditions: Opioid Use Disorder, Opioid Use
Interventions: Sub-acute stabilization; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 40,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Insomnia, Nightmares Associated With Trauma and Stress, Nightmares, PTSD - Post Traumatic Stress Disorder
Interventions: Cognitive Behavioral Therapy for Insomnia, Cognitive Behavioral Therapy for Insomnia and Nightmares, Sleep Education, Sleep Education enhanced with Nightmare Education; Behavioral
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Solid Tumor
Interventions: MSC2363318A, MSC2363318A plus Trastuzumab, MSC2363318A plus Tamoxifen; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more

Conditions: HIV
Interventions: Acute Treatment Interruption; Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Interaction, Adverse Herb-Drug, Diabetes Mellitus, Type 2
Interventions: Midazolam Hcl 1Mg/Ml Inj, Goldenseal (Hydrastis canadensis); Drug · Dietary Supplement
Lead sponsor: Washington State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Stroke, Balance; Distorted
Interventions: Body weight support system control group, Body weight support system with balance perturbations; Device
Lead sponsor: Gaylord Hospital, Inc; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Wallingford, Connecticut

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: atomoxetine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 1,553 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2009
U.S. locations: 70
States / cities: Birmingham, Alabama • Phoenix, Arizona • El Centro, California + 67 more

Conditions: Alcohol Use Disorder
Interventions: Ethanol, Saline; Drug
Lead sponsor: Lauren Whitehurst; Other
Eligibility: 21 Years to 45 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome/Acute Myeloid Leukemia
Interventions: Azacitidine, Cytarabine, Decitabine, Laboratory Biomarker Analysis, Midostaurin, Nivolumab; Drug · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 60 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 506
States / cities: Anchorage, Alaska • Tucson, Arizona • Hot Springs, Arkansas + 337 more

Conditions: AML, Acute Myeloid Leukemia
Interventions: DREAMLAND, CERENA; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Boston, Massachusetts • Durham, North Carolina • Seattle, Washington

Conditions: Stroke, Stroke, Acute, Balance; Distorted, Balance; Impairment, Gait, Unsteady
Interventions: Body weight support system control group, Body weight support system with balance perturbations; Device
Lead sponsor: Gaylord Hospital, Inc; Other
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Wallingford, Connecticut • Washington D.C., District of Columbia • Sandwich, Massachusetts + 1 more

Search by objective public record fields.

Safety of and Immune Response to a DNA HIV Vaccine (VRC-HIVDNA009-00-VP) in HIV Infected Individuals With Acute HIV Infection

Feasibility Study of IV Recombinant Tissue Plasminogen Activator (rtPA) vs. Primary Endovascular Therapy for Acute Ischemic Stroke

A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection

Controlling Acute or Early HIV Infection With Antiretroviral Drugs, Without a Candidate Vaccine.As Reported Previously, the Candidate Vaccie Was Not Provided by the Maufacturer as Promised

Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected With HIV

Therapeutic Vaccination Followed by Treatment Interruption in HIV Infected Patients

Real World Evidence of SI-BONE's iFuse TORQ TNT Advancing Treatment of Pelvic Ring Fractures

FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia

Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function

Psychological Intervention Mobile App for Patients With AML

Botanical Therapy for Acute Viral Respiratory Infections

Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection

Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV Infection

Overdose Recovery and Care Access (ORCA) Qualitative Stakeholder Interviews and County-level Data

Restorative Early Sleep Treatment After the Emergency Department

First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies

Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption

Clinical Evaluation of the Pharmacokinetic Goldenseal-Metformin Interaction in Diabetic Patients

Explorations of the Benefits of the ZeroG TRiP System to Improve Balance in Patients Following Stroke

Long-Term, Open Label Atomoxetine Study

The Effects of Sex Hormones and Alcohol on Sleep

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Psychological Mobile App for Patients With AML

A Multisite Exploration of Balance Perturbations With and Without Body Weight Support